# CAR-T Cell Therapy Combined With Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Multiple Myeloma

> **NCT06913179** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Xuzhou Medical University** · enrollment: 30 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** All enrolled patients will first receive CAR-T cell therapy. Patients who achieve complete remission following CAR-T infusion will subsequently undergo allo-HSCT

## Key facts

- **NCT ID:** NCT06913179
- **Lead sponsor:** Xuzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-04-01
- **Primary completion:** 2027-03-31
- **Final completion:** 2028-03-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06913179

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06913179, "CAR-T Cell Therapy Combined With Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06913179. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*